|Description||A tumour marker. Although CA 19.9 is frequently elevated in patients with Ca pancreas and is used for monitoring therapy, it is not useful in the diagnosis of Ca pancreas.|
|Indication||Monitors pancreatic and colorectal cancers. High levels diagnositic in pancreatic cancer.
|Additional Info||5% of the population cannot synthesise CA 19-9 (individuals with Lewis neg blood group antigens).
Elevations may be seen in cirrhosis and benign biliary tract disease. PLEASE NOTE: TEST CAN ONLY BE ADDED TO A SAMPLE WITHIN 8 HOURS OF COLLECTION|
|Interpretation||Although CA 19.9 is frequently elevated in patients with Ca pancreas and is used for monitoring therapy, it is not useful in the diagnosis of Ca pancreas.
|Collection Conditions||No restrictions|
|Min. Vol||0.5 mL|
|Ref. Range (Male)||<33|
|Ref. Range (Female)||<33|
|Ref. Range (Paed)|| |
|Ref. Range Notes||
|IP Acute TAT||Refer to Website|
|IP Routine TAT||Refer to Website|
|GP Acute TAT||- Contact Laboratory|
|GP Routine TAT||12 hours|
|Turnround Comment||Minimum re-test interval = 14 days|
Originally edited by : JHB. Review due on 23/05/2017 08:00:13. Published By Sylvia McLellan on 23/05/2016 08:00:13.